High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders — Stella

Home/Plasma Cell Disorder/

View on ClinicalTrials.gov

Recruiting

Back to Plasma Cell Disorder trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Key details

Phase

Early testing

Sponsor

University of Arkansas

Collaborators

University of Iowa

Enrollment target

~18 participants

Started

July 2024

Primary completion

April 2027

Age range

18 Years – 100 Years

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

Last updated June 2025